New Treatment Could Upend Standard of Care for Advanced Prostate Cancer

Video

Medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.

In a recent interview with Pharmacy Times, medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer, and how this drug could interrupt the typical standard of care. These new findings will be presented at the American Society of Clinical Oncology 2021 annual meeting.

Morris said the typical sequence for a patient with advanced prostate cancer would begin with a testosterone-lowering agent in combination with an androgen receptor pathway inhibitor or chemotherapy, followed by a treatment that they had not previously received. If it were to be approved in the future, Morris said 177Lu-PSMA-617 could represent a new option.

Related Videos
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
cancer pain management | Image Credits: © Burlingham - stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
multiple myeloma clinical trial/Image Credits: © Studio Romantic - stock.adobe.com
3d rendered illustration of lung cancer 3D illustration - Image credit:  appledesign | stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
Mayo Clinic oncology pharmacy
© 2024 MJH Life Sciences

All rights reserved.